19-10798543-C-T

Variant names:

• chr19-10798543-C-T
• rs121909091
• NM_001005361.3:c.1393C>T

Variant summary

Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PP3 PS3 PS4 PP1_Strong

This summary comes from the ClinGen Evidence Repository: The variant NM_001005361.3:c.1393C>T in DNM2 is a missense variant predicted to cause substitution of arginine by tryptophan at amino acid 465 (p.Arg465Trp). The highest population minor allele frequency in gnomAD v4.1 is 0.000001695 (2/1180018 alleles) in the European (non-Finnish) population (PM2_Supporting, BS1, and BA1 are not met). The REVEL computational prediction analysis tool produced a score of 0.83, which is above the threshold necessary to apply PP3. This variant has been reported in at least six probands with confirmed centronuclear myopathy (PS4; PMID:16227997, 19130742, 22613877, 26908122, 28740838, 34463354, 34595679). In addition, it segregated in five affected individuals in one family (PP1_Strong; PMID:16227997). Functional studies have demonstrated that this variant increases GTPase activity compared to wildtype dynamin (PMIDs: 20529869, 26199319). Several knock-in mouse models with the variant have been created and show muscle defects, progressive atrophy and morphological abnormalities similar to those observed in human biopsies, and DNM2 reduction has been shown to rescue the phenotype in mice (PS3; PMIDs: 20858595, 30291191). In summary, this variant meets the criteria to be classified as pathogenic for autosomal dominant centronuclear myopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen Congenital Myopathies VCEP: PP3, PS4, PP1_Strong, PS3. (ClinGen Congenital Myopathies VCEP specifications version 1; 8/7/2024) LINK:https://erepo.genome.network/evrepo/ui/classification/CA172098/MONDO:0018947/148

• Frequency:
  • Genomes: not found (cov: 31)
  • Exomes 𝑓: 0.0000014 (0 hom.)
• Consequence: DNM2 NM_001005361.3 missense
• Clinical Significance: Pathogenic reviewed by expert panel P:17 U:1
• Conservation: PhyloP100: 1.07

Genes affected

DNM2 (HGNC:2974): (dynamin 2) Dynamins represent one of the subfamilies of GTP-binding proteins. These proteins share considerable sequence similarity over the N-terminal portion of the molecule, which contains the GTPase domain. Dynamins are associated with microtubules. They have been implicated in cell processes such as endocytosis and cell motility, and in alterations of the membrane that accompany certain activities such as bone resorption by osteoclasts. Dynamins bind many proteins that bind actin and other cytoskeletal proteins. Dynamins can also self-assemble, a process that stimulates GTPase activity. Five alternatively spliced transcripts encoding different proteins have been described. Additional alternatively spliced transcripts may exist, but their full-length nature has not been determined. [provided by RefSeq, Jun 2010]

ACMG classification

Verdict is Pathogenic. Variant got 13 ACMG points.

• PS3: For more information check the summary or visit ClinGen Evidence Repository.
• PS4: For more information check the summary or visit ClinGen Evidence Repository.
• PP1: For more information check the summary or visit ClinGen Evidence Repository.
• PP3: For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
DNM2	NM_001005361.3	c.1393C>T	p.Arg465Trp	missense_variant	Exon 11 of 21	ENST00000389253.9	NP_001005361.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
DNM2	ENST00000389253.9	c.1393C>T	p.Arg465Trp	missense_variant	Exon 11 of 21	5	NM_001005361.3	ENSP00000373905.4

Frequencies

GnomAD3 genomes Cov.: 31

GnomAD4 exome AF: 0.00000137 AC: 2 AN: 1461872 Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1 AN XY: 727240

Gnomad4 AFR exome AF: 0.00

Gnomad4 AMR exome AF: 0.00

Gnomad4 ASJ exome AF: 0.00

Gnomad4 EAS exome AF: 0.00

Gnomad4 SAS exome AF: 0.00

Gnomad4 FIN exome AF: 0.00

Gnomad4 NFE exome AF: 0.00000180

Gnomad4 OTH exome AF: 0.00

GnomAD4 genome Cov.: 31

ClinVar

Significance: Pathogenic

Submissions summary: Pathogenic:17 Uncertain:1

Revision: reviewed by expert panel

Submissions by phenotype

not provided Pathogenic:6

Sep 25, 2023

Revvity Omics, Revvity

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

-

Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+

Significance: Pathogenic

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

-

Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)

Significance: Likely pathogenic

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

Dec 08, 2022

GeneDx

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

Published functional studies demonstrate that R465W increases GTPase activity and leads to a highly stable dynamin complex that is resistant to normal disassembly; knock-in mice show muscle defects, progressive atrophy, and muscle biopsy changes similar to humans (Cowling et al., 2011; Wang et al., 2010; Durieux et al., 2010); Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 26908122, 26199319, 27447704, 22369075, 16227997, 19623537, 20227276, 26633545, 22613877, 22451505, 22096584, 21762456, 21514436, 20529869, 28466468, 28740838, 19130742, 31017801, 31628461, 29246969, 32721234, 35282416, 33187981, 33097808, 35244154, 34595679, 35217605, 30291191, 32315611, 34463354, 20858595) -

-

Genome Diagnostics Laboratory, University Medical Center Utrecht

Significance: Pathogenic

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

Nov 22, 2023

Mayo Clinic Laboratories, Mayo Clinic

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

PP3, PM2_moderate, PM6, PS3, PS4 -

Autosomal dominant centronuclear myopathy Pathogenic:5

Sep 25, 2023

Laboratory of Medical Genetics, National & Kapodistrian University of Athens

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

PM2, PP2, PP3, PP5 - The variant has been reported in ClinVar as Pathogenic by other laboratories (Variation ID 7281). This variant has been previously reported as causative for centronuclear myopathy. (PMID:34837441). -

Feb 04, 2022

Institute of Human Genetics, University Hospital Muenster

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

ACMG categories: PS3,PM1,PM2,PP3,PP5 -

Nov 01, 2005

OMIM

Significance: Pathogenic

Review Status: no assertion criteria provided

Collection Method: literature only

- -

Nov 06, 2013

Baylor Genetics

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant has been previously reported as disease-causing and was found once in our laboratory in a 43-year-old male with centronuclear myopathy. -

Feb 08, 2022

MGZ Medical Genetics Center

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Centronuclear myopathy Pathogenic:3

Feb 08, 2013

Genetic Services Laboratory, University of Chicago

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Aug 07, 2024

ClinGen Congenital Myopathies Variant Curation Expert Panel, ClinGen

Significance: Pathogenic

Review Status: reviewed by expert panel

Collection Method: curation

The variant NM_001005361.3:c.1393C>T in DNM2 is a missense variant predicted to cause substitution of arginine by tryptophan at amino acid 465 (p.Arg465Trp). The highest population minor allele frequency in gnomAD v4.1 is 0.000001695 (2/1180018 alleles) in the European (non-Finnish) population (PM2_Supporting, BS1, and BA1 are not met). The REVEL computational prediction analysis tool produced a score of 0.83, which is above the threshold necessary to apply PP3. This variant has been reported in at least six probands with confirmed centronuclear myopathy (PS4; PMID: 16227997, 19130742, 22613877, 26908122, 28740838, 34463354, 34595679). In addition, it segregated in five affected individuals in one family (PP1_Strong; PMID: 16227997). Functional studies have demonstrated that this variant increases GTPase activity compared to wildtype dynamin (PMIDs: 20529869, 26199319). Several knock-in mouse models with the variant have been created and show muscle defects, progressive atrophy and morphological abnormalities similar to those observed in human biopsies, and DNM2 reduction has been shown to rescue the phenotype in mice (PS3; PMIDs: 20858595, 30291191). In summary, this variant meets the criteria to be classified as pathogenic for autosomal dominant centronuclear myopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen Congenital Myopathies VCEP: PP3, PS4, PP1_Strong, PS3. (ClinGen Congenital Myopathies VCEP specifications version 1; 8/7/2024) -

Apr 07, 2024

Molecular Genetics, Royal Melbourne Hospital

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This sequence change in DNM2 is predicted to replace arginine with tryptophan at codon 465, p.(Arg465Trp). The arginine residue is highly conserved (100 vertebrates, Multiz Alignments), and is located in the dynamin central region. There is a large physicochemical difference between arginine and tryptophan. This variant is absent from the population database gnomAD v2.1 and v3.1. The variant is a commonly reported cause of centronuclear myopathy in different populations and segregates with disease in multiple families (PMID: 16227997, 22396310, 23394783, 26908122, 34837441). A knock-in mouse model for the variant develops myopathy (PMID: 20858595). Computational evidence predicts a deleterious effect for the missense substitution (REVEL = 0.83). Based on the classification scheme RMH Modified ACMG/AMP Guidelines v1.6.1, this variant is classified as PATHOGENIC. Following criteria are met: PP1_Strong, PP3, PS3_Moderate, PS4, PM2_Supporting. -

Charcot-Marie-Tooth disease dominant intermediate B Pathogenic:1 Uncertain:1

Nov 04, 2024

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 465 of the DNM2 protein (p.Arg465Trp). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with autosomal dominant centronuclear myopathy (PMID: 16227997, 22396310). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 7281). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on DNM2 protein function. Experimental studies have shown that this missense change affects DNM2 function (PMID: 20858595, 22096584, 22369075, 27343996). For these reasons, this variant has been classified as Pathogenic. -

Jan 06, 2016

Inherited Neuropathy Consortium Ii, University Of Miami

Significance: Uncertain significance

Review Status: no assertion criteria provided

Collection Method: literature only

- -

Abnormality of the musculature Pathogenic:1

Jul 10, 2021

Kariminejad - Najmabadi Pathology & Genetics Center

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

DNM2-related disorder Pathogenic:1

Jun 19, 2024

PreventionGenetics, part of Exact Sciences

Significance: Pathogenic

Review Status: no assertion criteria provided

Collection Method: clinical testing

The DNM2 c.1393C>T variant is predicted to result in the amino acid substitution p.Arg465Trp. This is one of the most common variants reported to be causative for autosomal dominant centronuclear myopathy (see, for example, Bitoun et al 2005. PubMed ID: 16227997; Cowling et al 2011. PubMed ID: 21514436; Koutsopoulos et al 2011. PubMed ID: 22096584). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
AlphaMissense	Pathogenic	0.91
BayesDel_addAF	Pathogenic	0.37	D
BayesDel_noAF	Pathogenic	0.29
CADD	Pathogenic	31
DANN	Pathogenic	1.0
DEOGEN2	Pathogenic	0.96	.;.;.;D;.;D
Eigen	Uncertain	0.59
Eigen_PC	Uncertain	0.44
FATHMM_MKL	Uncertain	0.95	D
LIST_S2	Pathogenic	0.98	D;D;D;D;D;D
M_CAP	Uncertain	0.23	D
MetaRNN	Pathogenic	0.97	D;D;D;D;D;D
MetaSVM	Uncertain	0.62	D
MutationAssessor	Pathogenic	3.6	H;H;H;H;H;.
PrimateAI	Pathogenic	0.83	D
PROVEAN	Pathogenic	-7.2	.;D;D;D;D;.
REVEL	Pathogenic	0.83
Sift	Pathogenic	0.0	.;D;D;D;D;.
Sift4G	Pathogenic	0.0	D;D;D;D;D;D
Polyphen		1.0	.;D;.;D;.;.
Vest4		0.91
MutPred		0.91		Loss of disorder (P = 0.0057);Loss of disorder (P = 0.0057);Loss of disorder (P = 0.0057);Loss of disorder (P = 0.0057);Loss of disorder (P = 0.0057);.;
MVP		0.94
MPC		2.2
ClinPred		1.0	D
GERP RS		2.3
RBP_binding_hub_radar		0.0
RBP_regulation_power_radar		1.7
Varity_R		0.89
gMVP		0.86

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.010		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs121909091; hg19: chr19-10909219; COSMIC: COSV58963902; COSMIC: COSV58963902;